-
Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Comparative Efficacy Safety and Discontinuation of Inhaled Levodopa for Patients With Parkinson’s Disease: A Network Meta-Analysis
Sep 9, 2025, 16:22 PM -
Clinical Outcome Assessments in Drug Approvals: Trends and Insights From FDA; EMA Labeling 2018-2023
Sep 9, 2025, 16:22 PM -
Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings
Sep 9, 2025, 16:22 PM -
Navigating Uncharted Waters: Challenge of Anticipating Technologies Subject to Environmental Considerations in Future HTA
Sep 9, 2025, 16:22 PM -
Considerations for Modeling Caregiver Spillover Within Economic Evaluations for Neurological Disorders: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Multiple Sclerosis (MS)
Sep 9, 2025, 16:22 PM -
Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden
Sep 9, 2025, 16:22 PM -
Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Dimethyl Fumarate for the Treatment of Relapsing/Remitting Multiple Sclerosis in Iraq
Sep 9, 2025, 16:22 PM -
Effectiveness and Safety of Radiofrequency Nucleolysis for Chronic or Acute Low Back Pain
Sep 9, 2025, 16:22 PM -
KRAS Alterations in Advanced Non-Small Cell Lung Cancer (NSCLC): Temporal Trends in Testing Patterns and Targeted Treatment Use Across Europe Between 2018 and 2024
Sep 9, 2025, 16:22 PM -
Cost-Minimization Analysis and Economic Impact in EGPA: Evidence From MANDARA
Sep 9, 2025, 16:22 PM -
Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions
Sep 9, 2025, 16:22 PM -
Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy
Sep 9, 2025, 16:22 PM -
Direct and Indirect Economic Burden Due to Chronic Limb-Threatening Ischemia (CLTI) in Germany
Sep 9, 2025, 16:22 PM -
Self-Reported Health Related Quality of Life (HRQoL) in Patients With Ischemic Heart Disease: A Randomized Controlled Trial on Digital Health Pharmacist Interventions
Sep 9, 2025, 16:22 PM -
Economic Evaluation of Synovial Biopsy-Guided Treatment Strategy After TNF-Alpha Inhibitor Failure in Rheumatoid Arthritis
Sep 9, 2025, 16:22 PM -
The Clawbacks Paradox: When Abusing a Simple Approach Has the Most Complicated and Problematic Consequences for Patients and Healthcare Systems
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review to Identify Risk Factors and Symptoms of Long COVID-19 in Adult Indian Patients
Sep 9, 2025, 16:22 PM -
AI in Pragmatic Literature Reviews: A Scoping Review of Current Guidance and Development of a Framework for Integration
Sep 9, 2025, 16:22 PM
